公开(公告)号：US11642350B2

公开(公告)日：2023-05-09

申请号：US16495350

申请日：2018-03-22

申请人： Singapore Health Services PTE LTD ,  Santen Pharmaceutical Co., Ltd.

发明人： Tiang Hwee Donald Tan ,  Roger Wilmer Beuerman ,  Seang-Mei Saw ,  Aradhana Upadhyay ,  Masatomo Kato ,  Takaaki Inaba

IPC分类号： A61K31/5386 ,  A61P27/10 ,  A61K9/00

CPC分类号： A61K31/5386 ,  A61K9/0048 ,  A61P27/10

摘要： The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

公开(公告)号：US08975256B2

公开(公告)日：2015-03-10

申请号：US13937447

申请日：2013-07-09

申请人： Santen Pharmaceutical Co., Ltd.

发明人： Mamoru Matsuda ,  Toshiyuki Mori ,  Kenji Kawashima ,  Minoru Yamamoto ,  Masatomo Kato ,  Miwa Takai ,  Masato Nagatsuka ,  Sachiko Kobayashi

IPC分类号： A61K31/535 ,  A61K31/44 ,  A01N43/40 ,  C07D241/46 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

CPC分类号： C07D241/46 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

摘要： A 1,2,3,4-tetrahydroquinoxaline compound represented by the following formula: In the formula (1), R1 represents substituents such as a halogen, an alkyl, a cycloalkyl, an aryl or a heterocyclic group; p represents 0 to 5; R2 represents substituents such as a halogen, an alkyl, a hydroxyl or an alkoxy group; q represents 0 to 2; R3 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkylcarbonyl or an arylcarbonyl group; R4 and R5 independently represent substituents such as hydrogen, a halogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; R6 represents substituents such as hydrogen, an alkyl, an alkenyl, an alkynyl, a cycloalkyl, an aryl or a heterocyclic group; A represents an alkylene; R7 represents OR8, NR8R9, SR8, S(O)R8, S(O)2R8; R8 and R9 independently represent substituents such as hydrogen, an alkyl or an alkenyl; and X represents O or S.

摘要翻译： 由下式表示的1,2,3,4-四氢喹喔啉化合物：式（1）中，R 1表示卤素，烷基，环烷基，芳基或杂环基等取代基。 p表示0〜5; R 2表示取代基，例如卤素，烷基，羟基或烷氧基; q表示0〜2; R3表示取代基，例如氢，烷基，烯基，烷基羰基或芳基羰基; R4和R5独立地表示取代基，例如氢，卤素，烷基，烯基，炔基，环烷基，芳基或杂环基; R6表示取代基，例如氢，烷基，烯基，炔基，环烷基，芳基或杂环基; A表示亚烷基; R 7表示OR 8，NR 8 R 9，SR 8，S（O）R 8，S（O） R8和R9独立地表示取代基，例如氢，烷基或烯基; X表示O或S.

公开(公告)号：US11419880B2

公开(公告)日：2022-08-23

申请号：US17546895

申请日：2021-12-09

申请人： SANTEN PHARMACEUTICAL CO., LTD.

发明人： Masatomo Kato ,  Tomoko Oda ,  Kazutaka Kido

IPC分类号： A61K31/575 ,  A61P27/10 ,  A61K9/00

摘要： The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.